Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

Published on January 11, 2022

The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

Continue reading on website
Other news

The SPAC boom was a failure, yeah?

January 11, 2022
It’s painful to watch SPAC deals collapse post-combination. You can viscerally feel dreams melting away to disappointment as founders, employees and investors still holding shares in the newly public entities watch their wealth dwindle.The mess is not sector-specific. Media? Not a good SPAC target. Insurtech? Nope. 3D printing? Not looking good. E-scooters? Nerp. Hardware and software for apartmen

BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

January 11, 2022
BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.